drugset / Trial / NCT02187822
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
Phase 1
Terminated
15 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Cortice Biosciences, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.
Timeline
- Start
- 2014-10-09
- Primary completion
- 2018-02-20
- Completion
- 2018-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPI 287 | Small molecule | 14 mg/m2 | Intravenous |